Osteocalcin and bone-specific alkaline phosphatase in sickle cell haemoglobinopathies.
Osteocalcin or bone gamma-carboxyglutamic acid (gla) protein and Bone-specific alkaline phosphatase (b-AP) total protein levels were evaluated as indicators of bone turnover in twenty patients with sickle cell haemoglobinopathies and in twenty normal healthy individuals. The serum bone-specific alkaline phosphatase total protein level was measured by immunoradiometric (IRMA) method. The concentrations of serum bone-specific alkaline phosphatase total protein were higher in the study group than in the control group [P < 0.05]. The serum osteocalcin (BGP) showed no significant difference with the control healthy subjects. There was no correlation between the serum osteocalcin and serum bone-specific alkaline phosphatase total protein in the patient group. In conclusion, serum bone-specific alkaline phosphatase total protein determined or measured by IRMA can be considered a sensitive marker of bone turnover and could be especially useful as valuable non-invasive biochemical marker for identifying sickle cell patients with bone complications.
Azinge
E C
EC
Department of Clinical Pathology, College of Medicine, University of Lagos, Lagos, Nigeria.
Bolarin
D M
DM
D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000175:diagnosis; D015415:Biomarkers / Q000097:blood; D001842:Bone and Bones / Q000201:enzymology* / Q000378:metabolism; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*
D015415:Biomarkers; D015675:Osteocalcin; D000469:Alkaline Phosphatase